⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XENE News
Xenon Pharmaceuticals Inc
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
globenewswire.com
XENE
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
globenewswire.com
XENE
Form 8-K
sec.gov
XENE
Form 8-K
sec.gov
XENE
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
XENE
Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight
prnewswire.com
LIVN
PTC
UCB
XENE
AQST
TAK
BHVN
KNOP
VRTX
SUPN
GSK
SNY
MD
Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas
globenewswire.com
GSK
RGNX
OMER
XENE
NMRA
Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas
globenewswire.com
GSK
RGNX
OMER
XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
XENE
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
globenewswire.com
XENE